NFLymSI-18 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Cancer Symptom Index - 18 Item Version For patients with Lymphoma (NHL); a FACT/NCCN-Lymphoma Symptom Index LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) Lymphoma Symptom Index-18 (FLymSI-18) is a shortened, targeted measure for patients with lymphoma. Patients with advanced Lym (n = 50) rated the significance of 40 symptoms, and hematologist–oncologists (n = 10) rated these symptoms according to importance and disease-related or treatment-related origin. Patient symptom priorities were unified with clinician priorities for symptom measurement in lymphoma. Reliability estimates indicate that the FLymSI-18 has acceptable internal consistency (α = 0.87), content validity and concurrent validity as indicated by moderate to strong correlations with the FACIT (Functional Assessment of Chronic Illness Therapy). Overall, the FLymSI-18 provides evidence for its reliability and validity as a brief assessment of the most important symptoms associated with advanced lymphoma in clinical trials research. MEASURE NAME: National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Cancer Symptom Index - 18 Item Version (NFLymSI-18) VERSION: 2 NUMBER OF ITEMS: 18 PATIENT POPULATION: Lymphoma patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Disease-Related Symptoms – Physical, Disease-Related Symptoms – Emotional, Treatment Side Effects, Function/Well-Being TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. RELATED MEASURES: FACT-Lym , FACT-Leu , FACT-G DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the NFLymSI-18 can be obtained by registering for permission. Users are not permitted to translate the NFLymSI-18 without permission from FACIT.org. Permission from FACIT.org to translate the NFLymSI-18 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Hlubocky, F., Webster, K., Beaumont, J., Cashy, J., Paul, D., Abernethy, A., Syrjala, K., Von Roenn, J., & Cella, D. A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy-Lymphoma Symptom Index. Leukemia & Lymphoma 2013; 54(9): 1942-1946. doi: 10.3109/10428194.2012.762977. Rosenbloom, S., Yount, S., Yost, K., Hampton, D., Paul, D., Abernethy, A., Jacobsen, P., Syrjala, K., Von Roenn, J., & Cella, D. Development and validation of eleven symptom indices to evaluate response to chemotherapy for advanced cancer: Measurement compliance with regulatory demands. Farquhar, I., Summers, K., Sorkin, A. (Eds.). The Value of Innovation: Impacts on Health, Life Quality and Regulatory Research. Emerald Group Publishing Inc. 2007; 16: 53-66. doi: 10.1016/S0194-3960(08)16003-6. Webster KA, Zola AR, Corona M, Patten EA, Karmali R, Gordon L, Ma S, Winter JN, Upton A, Peipert JD; NFLymSI-18 Working Group. Validation and Clinical Meaningfulness of the 18-item National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) Lymphoma Symptom Index (NFLymSI-18) in Patients with Lymphoma. Value Health. 2026 Apr 17:S1098-3015(26)02388-0. doi: 10.1016/j.jval.2026.03.2244. Epub ahead of print. PMID: 42002076. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-Lym Functional Assessment of Cancer Therapy – Lymphoma LEARN MORE FACT-Leu Functional Assessment of Cancer Therapy – Leukemia LEARN MORE FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE

View all available languages for this measure. BACK FACT-NP Languages Chinese – Traditional English Thai

Download this measure in English. BACK COST English Downloads Download PDF Download DOC

Download scoring documents for this measure. BACK FACT-GP Scoring Downloads Download DOC

Download scoring documents for this measure. BACK FACT-M Scoring Downloads Download DOC

FKSI-23 Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 23 Item Version For patients with Kidney Cancer, a 23 item scale LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The FKSI-23 is a brief symptom index for assessing quality of life for localized and advanced kidney cancer patients comprised of items from the FACIT Measurement System. It is composed of 23 items. MEASURE NAME: Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 23 Item Version (FKSI-23) VERSION: 1 NUMBER OF ITEMS: 23 PATIENT POPULATION: Kidney cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Disease-Related Symptoms (Physical), Disease-Related Symptoms (Emotional), Treatment Side-Effects, Functional Well-Being, RCC TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale and total scores possible. RELATED MEASURES: NFKSI-19 , FKSI-DRS , FKSI-15 DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FKSI-23 can be obtained by registering for permission. Users are not permitted to translate the FKSI-23 without permission from FACIT.org. Permission from FACIT.org to translate the FKSI-23 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cristiane Decat Bergerot et al. Development of a FKSI-23: A new bespoke health-related quality of life (HRQOL) questionnaire for the advanced and adjuvant setting in renal cell carcinoma (RCC). JCO 43, 526-526(2025). DOI:10.1200/JCO.2025.43.5_suppl.526 Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures NFKSI-19 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 19 Item Version LEARN MORE FKSI-DRS Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - Disease Related Symptoms LEARN MORE FKSI-10 Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 15 Item Version LEARN MORE

FAIT-U Functional Assessment of Incontinence Therapy – Urinary LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FAIT-U measure: MEASURE NAME: Functional Assessment of Incontinence Therapy – Urinary (FAIT-U) VERSION: 4 NUMBER OF ITEMS: 38 PATIENT POPULATION: Patients 18 and older with urinary incontinence RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Urinary Incontinence Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FAIT-F , FACT-Bl , FACT-Bl-Cys DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FAIT-U can be obtained by registering for permission. Users are not permitted to translate the FAIT-U without permission from FACIT.org. Permission from FACIT.org to translate the FAIT-U may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FAIT-F Functional Assessment of Incontinence Therapy – Fecal LEARN MORE FACT-Bl Functional Assessment of Cancer Therapy – Bladder LEARN MORE FACT-Bl-Cys Functional Assessment of Cancer Therapy – Bladder – Cystectomy LEARN MORE

Download this measure in English. BACK NFBSI-16 English Downloads Download PDF Download DOC

FACT-Taxane Functional Assessment of Cancer Therapy – Taxane For patients receiving Taxane therapy LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACT-Taxane measure: MEASURE NAME: Functional Assessment of Cancer Therapy – Taxane (FACT-Taxane) VERSION: 4 NUMBER OF ITEMS: 43 PATIENT POPULATION: Cancer patients 18 and older receiving taxane therapy RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Taxane Therapy Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FACT/GOG-NTX, FACT/GOG-NTX-4 , FACT/GOG-NTX-12 , FACT/GOG-NTX-13 DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-Taxane can be obtained by registering for permission. Users are not permitted to translate the FACT-Taxane without permission from FACIT.org. Permission from FACIT.org to translate the FACT-Taxane may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cella, D., Peterman, A., Hudgens, S., Webster, K., & Socinski, M. Measuring the side effects of taxane therapy in oncology: The Functional Assessment of Cancer Therapy-Taxane (FACT-Taxane). Cancer2003; 98(4): 822-831. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT/GOG-NTX Functional Assessment of Cancer Therapy/Gynecologic Oncology Group – Neurotoxicity LEARN MORE FACT/GOG-NTX-4 Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity 4 Item Version LEARN MORE FACT/GOG-NTX-12 Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity 12 Item Version LEARN MORE

Download this measure in English. BACK FACIT-BTCSQ English Downloads Download PDF - Baseline Download DOC - Baseline Download PDF - On Therapy Download DOC - On Therapy

View all available languages for this measure. BACK CRRS Languages Danish English Farsi

The FACIT Measurement System is a collection of over 700 items, 130 pediatric items, and 100 validated measures targeted to the management of chronic illness. FACIT Measures & Searchable Library OVERVIEW The FACIT Measurement System is a collection of over 700 items, 130 pediatric items, and 100 validated measures targeted to the management of chronic illness. "FACIT" (Functional Assessment of Chronic Illness Therapy) was adopted as the formal name of the measurement system in 1997 to portray the expansion of the "FACT" (Functional Assessment of Cancer Therapy) measures into other chronic illnesses and conditions. The measurement system, under development since 1988, is a comprehensive collection of patient reported measures that assess general health-related quality of life (HRQoL) and specific disease- and treatment-related concerns across multiple chronic illnesses and the general population. The measurement system (originally referred to as the Functional Assessment of Cancer Therapy, or FACT) emerged from a conceptual framework for quality of life in the context of health status that is centered on two essential principles: subjectivity and multidimensionality. HRQoL is uniquely personal, defined by patient experiences and influenced by one’s subjective perspective. Therefore, HRQoL is best assessed by direct-report. HRQoL is multidimensional, including, but not limited to symptoms, side effects, and functional status. It also includes more general appraisals of life quality and value. Meaningful assessment comes from asking patients about these distinct, yet often correlated areas of function and well-being. There is general consensus that key domains of HRQoL include physical, functional, emotional, and social/family well-being. Physical well-being refers to perceived and observed bodily function or disruption and includes symptoms such as pain, fatigue, and nausea. Functional well-being refers to one’s ability to perform the activities related to one’s personal needs, ambitions, or social role and includes things like ability to work, sleep, and enjoy life. Emotional well-being covers positive and negative affect as well as life enjoyment and appreciation. Social/family well-being includes a broader range of perceived support, leisure activities, family wellbeing, and intimacy. Over time, this framework has expanded to include additional targeted domains such as disease-specific symptoms and treatment side effects for more comprehensive and clinically relevant assessment Validation of the core measure allowed for the evolution of multiple disease, treatment, condition, and other targeted measures. FACIT scales are constructed to complement the FACT-G, addressing relevant disease-, treatment-, or condition-related issues not already covered in the general questionnaire. Each is intended to be as specific as necessary to capture the clinically-relevant problems associated with a given condition or symptom, yet general enough to allow for comparison across diseases, and extension, as appropriate, to other chronic medical conditions. The FACIT Measurement System now includes over 700 items, some of which have been translated into more than 80 languages. Assessment of any one patient is tailored so that the most-relevant questions are asked and administration time for any one assessment is usually less than 15 minutes. The majority of FACIT items have demonstrated face and content validity and were created with direct input from patients and expert clinicians. More recently, FACIT has expanded its catalog of items to the FACIT Searchable Library , where one can create a custom form using the site’s Build-a-PRO function and include only those FACIT items most relevant to one’s study or purpose. While doing so does not instantly validate the custom composition, it does create an opportunity to select specific items relevant to the research question at hand, using content valid items that have undergone careful translation into other languages. It also allows for the opportunity to pursue validation of the assembled set of questions using standard questionnaire validation practice. The practice of selecting an established, fixed FACIT measure is still recommended for any investigator or clinician wishing to obtain a valid, interpretable score on the endpoints provided by that FACIT measure. FACIT Measures FACIT Searchable Library Administration Scoring eCOA Guidance Interpretation Translation & Linguistic Validation Methodology Label Claims FACIT Utilities